Pfizer Licenses Chai Discovery’s AI Platform to Accelerate Biologics Research

Shots: Pfizer & Chai Discovery have entered into a licensing agreement, allowing Pfizer to integrate Chai’s AI-driven drug discovery platform into its biologics research workflows As per the deal, Pfizer will integrate Chai’s AI platform into its drug discovery engine, gaining early access to the Chai-3 model & a customized AI model built using Pfizer’s…

ByRidhi Rastogi4 days ago

NEWS

Lundbeck Partners with Cradle to Accelerate AI-Driven Biotherapeutics Discovery

Shots: Lundbeck and Cradle entered a partnership to leverage AI-powered protein engineering for the discovery and optimization of biotherapeutics, with an initial focus on 2 antibody programs targeting CNS diseases Lundbeck will deploy Cradle’s generative AI platform in its first end-to-end AI-guided protein engineering workflow, using iterative feedback from experimental data to discover & optimize…

ByRidhi RastogiJune 4, 2026

NEWS

Alnylam and Inceptive Enter ~$2B Collaboration to Accelerate AI-Powered Discovery of RNAi Therapeutics

Shots: Alnylam Pharmaceuticals & Inceptive Nucleics have entered into a strategic collaboration to accelerate the discovery of novel RNAi therapeutics The collaboration is valued at up to $2B, with $30M upfront, incl. cash & an equity investment in Inceptive. Inceptive will also receive additional preclinical, regulatory, & commercial milestone payments Collaboration combines Alnylam’s RNAi expertise…

ByRidhi RastogiJune 4, 2026

NEWS

Haisco Enters ~$3.05B License and Research Collaboration with Lilly to Develop Novel Medicines Across Multiple Therapeutic Areas

Shots: Haisco Pharmaceutical has entered into a licensing & research collaboration with Eli Lilly to develop novel medicines across multiple therapeutic areas As per the deal, Haisco will be responsible for the discovery & identification of ~5 target programs, while Lilly will lead IND-enabling studies, clinical development, & commercialization Lilly will gain exclusive global rights…

ByRidhi RastogiJune 1, 2026

EVENTS

Evolution Summit 2026 | Sep 28-29 | Park Hyatt Aviara Resort, San Diego, CA

The Evolution Summit returns September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA, bringing together leading clinical trial executives with innovative suppliers and solution providers in an invitation-only, premium setting. Expect visionary keynotes, real-world case studies, and interactive forums aligned to the most pressing challenges in clinical operations and…

BySaurabh ChaubeyMay 26, 2026

NEWS

QIAGEN Teams Up with NVIDIA to Advance AI-Driven Drug Discovery

Shots: QIAGEN to integrate its Digital Insights bioinformatics business with NVIDIA accelerated computing & the NVIDIA BioNeMo platform to strengthen AI applications in drug discovery Partnership leverages graph-based AI that apply retrieval & reasoning techniques across biomedical knowledge graphs to help researchers analyze complex biological data & validate AI-generated insights, supporting practical applications across the…

ByRidhi RastogiMay 20, 2026

NEWS

Isomorphic Labs Raises $2.1B in Series B Funding to Scale AI Drug Design Engine & Advance Pipeline

Shots: Isomorphic Labs has reported a $2.1B Series B financing round led by Thrive Capital, with participation from existing investors Alphabet & GV alongside new backers MGX, Temasek, CapitalG, & the UK Sovereign AI Fund The company plans to use the capital to further develop & deploy its AI-powered drug discovery platform, IsoDDE, accelerate internal…

ByRidhi RastogiMay 13, 2026

NEWS

Oxford BioTherapeutics Partners with BMS to Develop Next-Generation T-cell Engagers for Solid Tumors

Shots: Oxford BioTherapeutics has entered into a multi-year strategic collaboration with Bristol Myers Squibb (BMS) to discover and develop next-generation T-cell engager therapies targeting solid tumors Under the agreement, OBT will leverage its OGAP-Verify platform to identify tumor-selective targets and design & delivery of developed candidates, while Bristol Myers Squibb will lead subsequent clinical research,…

ByPrince GiriApril 10, 2026

MAGAZINE

PharmaShots Magazine-April-2026 Edition

Shots: AI is redefining compliance from reactive to predictive, as this April edition highlights how AI-powered systems are transforming regulatory oversight into a continuous, real-time, and data-driven function, enabling early risk detection, automated audits, and smarter regulatory collaboration across the pharma value chain. Strategic dealmaking and AI partnerships shape industry momentum, with March witnessing high-value…

ByAditya SinghApril 9, 2026

NEWS

Insilico Medicine and Eli Lilly Sign ~$2.75B Multi-Program AI-Driven Drug Discovery Collaboration

Shots: Insilico has entered into a drug discovery collaboration with Eli Lilly to accelerate the discovery & development of novel therapeutics across multiple therapeutic areas using Insilico’s Pharma.AI As per the deal, Lilly will gain exclusive global rights to develop, manufacture & commercialize Insilico’s preclinical oral candidates for select indications. Also, both will collaborate on…

ByRidhi RastogiMarch 30, 2026

Pfizer Licenses Chai Discovery’s AI Platform to Accelerate Biologics Research

Lundbeck Partners with Cradle to Accelerate AI-Driven Biotherapeutics Discovery

Alnylam and Inceptive Enter ~$2B Collaboration to Accelerate AI-Powered Discovery of RNAi Therapeutics

Haisco Enters ~$3.05B License and Research Collaboration with Lilly to Develop Novel Medicines Across Multiple Therapeutic Areas

Evolution Summit 2026 | Sep 28-29 | Park Hyatt Aviara Resort, San Diego, CA

QIAGEN Teams Up with NVIDIA to Advance AI-Driven Drug Discovery

Isomorphic Labs Raises $2.1B in Series B Funding to Scale AI Drug Design Engine & Advance Pipeline

Oxford BioTherapeutics Partners with BMS to Develop Next-Generation T-cell Engagers for Solid Tumors

PharmaShots Magazine-April-2026 Edition

Insilico Medicine and Eli Lilly Sign ~$2.75B Multi-Program AI-Driven Drug Discovery Collaboration

Contact US

FOLLOW US